Report Overview

The Australia Asthma Drugs market size stood at USD 474 million in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Asthma is a chronic lung disease characterized by narrowing of airways and continual, marked inflammation and in response to specific triggers, which are usually reversible. If the management of the conditions is not done properly, this may elevate the risk of Asthma attacks and even medical emergencies. Most, if not all, Asthma attacks are preventable, especially in adults. Notwithstanding this fact, there is a rising prevalence of Asthma, which is closely linked to the severity and mortality of the disease.

Preventive drugs for Asthma play a crucial role in managing the disease conditions and help pacify the risk of Asthma attacks. Drug therapies for Asthma have been evolving rapidly, driven by advances in the pharmacotherapy of Asthma. Research into expanding the various pathophysiologic processes related to Asthmatic response and triggers will lead to advanced classes of Asthma drugs with less toxicity.



Market Drivers

The rise in pollution levels in several industrialized nations has led to an increased presence of allergens triggering Asthma. This is a key factor driving the demand for preventive Asthma drugs. The rising incidence of Asthma in various parts of Australia, along with the morbidity associated with the disease, is a key factor accentuating the demand for preventive drugs. The rise in population with higher tobacco consumption and prolonged exposure to smoke of biomass fuels is adding to the prevalence of the disease.

Asthma Australia welcomes the new GSK Australia once-daily ARNUITY ELLIPTA Asthma treatment soon to be added to the shelves of Australian Pharmacies and listed on the Pharmaceutical Benefits Scheme, announced this week. Asthma Australia is the nations peak body representing the 2.7 million Australians with Asthma and with more than 15 Asthma inhalers now on the market it was important for both prescribers and patients to know how ARNUITY ELLIPTA fits in.

The market is majorly driven by increasing drug approvals, High prevalence of ASTHMA/AIDS. The increasing emphasis on the research and development of ASTHMA/AIDS drugs has led to several drug innovations in recent years. The increasing demand for therapeutic procedures and treatment methods has created a subsequent emphasis on the development of related drugs. The rising prevalence of ASTHMA/AIDS has resulted in the increased emphasis on the development of treatment methods and drugs associated with the treatment of this disease. Due to the increasing incidence of ASTHMA/AIDS, the ASTHMA/AIDS drug companies have witnessed massive growth opportunities in recent years.

Epidemiology of ASTHMA

Around 2.7 million Australians (11% of the total population) have Asthma, based on selfreported data from the201718Australian Bureau of Statistics (ABS) National Health Survey (NHS) (ABS 2018).